M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
JJP Biologics Reports Positive Top‑Line Phase I Data for JJP‑1212, Validating Innovation in Autoimmune Therapy
JJP Biologics reports positive Phase I results for JJP-1212, a first-in-class anti-CD89 antagonist, showing safety and promising efficacy in autoimmune and inflammatory diseases.
JJP Biologics has announced positive top-line results from its Phase I...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search